Equity Offerings

Shares of GSV Capital Corp (Nasdaq: GSVC), which has surged recently on the Facebook-IPO craze, is under heavy pressure early Friday after the company updated an equity offering filing with the SEC showing it will sell 6 million shares. This is up from the 3 million expected to be sold.

Shares last traded at $15.15, down 22%.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the pricing of an underwritten public offering of 6,800,000 shares of its common stock at a price to the public of $10.61 per share. The offering is expected to settle and close on February 15, 2012, subject to customary closing conditions. Barclays Capital Inc. is the sole book-running manager of the offering, and Halozyme has granted them a thirty (30) day option to purchase up to 1,020,000 shares of common stock. Halozyme intends to use the net proceeds from the offering to build commercial inventory for anticipated product launches, fund research and development of proprietary programs, and for general corporate purposes.

EV Energy Partners, L.P. (NASDAQ: EVEP) today announced that its public offering of 3,500,000 common units was priced at $67.95 per unit to the public. The Partnership expects the delivery to occur on February 15, 2012. In addition, the underwriters have an over-allotment option to purchase up to 525,000 common units. The offering was upsized to 3,500,000 common units from the original offering size of 3,200,000 common units.

Assuming no exercise of the over-allotment option, the Partnership expects to receive net proceeds from the offering of approximately $233 million, after deducting the underwriting discounts and commissions and estimated offering expenses, and including the Partnership's general partner's proportionate capital contribution.

The Partnership intends to use the net proceeds from the offering, including the proceeds from any exercise of the over-allotment option of common units, to repay indebtedness under its existing revolving credit facility.

Buckeye Partners, L.P. (NYSE: BPL) announced that it has entered into definitive agreements to sell to certain institutional investors an aggregate of 4,262,575 limited partnership units representing limited partner interests ("LP Units") in a registered direct offering for gross proceeds of approximately $250.0 million, before deducting placement agents fees and estimated offering expenses. The investors have agreed to purchase the LP Units for a price of $58.65 per LP Unit. Buckeye plans to use the net proceeds from this offering to fund indirectly a portion of the $260 million cash purchase price to acquire a marine terminal facility for liquid petroleum products in New York Harbor from Chevron U.S.A. Inc. and certain other growth capital expenditures, and, pending such uses, to reduce the indebtedness outstanding under its revolving credit facility.

The LP Units described above are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-178160), which was declared effective by the U.S. Securities and Exchange Commission ("SEC") on December 6, 2011.

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today the pricing of an underwritten public offering of 5,250,000 shares of its Class A common stock at a price of $15.09 per share to the public. All of the shares are being offered by Ironwood. The gross proceeds to Ironwood from this offering are expected to be approximately $79.2 million, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by Ironwood. The offering is expected to close on February 15, 2012, subject to the satisfaction of customary closing conditions.

The Company intends to use the net proceeds from this offering for general corporate purposes, including to further strengthen its balance sheet in advance of the potential market launch of linaclotide (if approved).